SPDL1 and gastric cancer: Similarly, Ando et al. analyzed the evolution of sPD-L1 levels in the plasma of NSCLC and gastric cancer patients under anti-PD-1 treatment and reported an association between reduced sPD-L1 after 4 cycles of treatment and tumor regression [29].